Contact Info
- 2492 Walnut Avenue
- Suite 100
- Tustin, CA 92780-7039
- Website: http://www.radient-pharma.com
- Phone: 714-505-4461
Verify Company Info
Business Description
We are the developer and worldwide marketer of Onko-Sure (R), non-invasive cancer blood test kit.
Financial Reporting/Disclosure
| Reporting Status | U.S. Reporting: SEC Filer |
| Audited Financials | Audited |
| Latest Report | Dec 31, 2011 10-K |
| CIK | 0000838879 |
| Fiscal Year End | 12/31 |
| OTC Market Tier | OTC Pink No Information |
Profile Data
| SIC - Industry Classification | 2834 - Pharmaceutical preparations |
| Incorporated In: | DE, USA |
| Year of Inc. | 1989 |
| Employees | 13 a/o Jun 09, 2011 |
Company Officers/Contacts
| Douglas MacLellan | CEO |
| Akio Ariura | CFO, COO |
Company Directors
| Douglas MacLellan | Chairman |
| Robert M. Beart | |
| Michael Boswell | |
| Leonard M.J. Reyno | |
| Robert L. Rooks |
Company Notes
- Note = Company delisted from NYSE Amex on 06/23/11
- Formerly=AMDL, Inc. until 9-2009
- Note=6-89 State of incorporation Colorado changed to Delaware
- Formerly=California Ventures, Inc. to 6-89
Service Providers
Auditor/Accountant Legal Counsel Investor Relations Firm
Not Available
RXPC Security Details
Share Structure
| Market Value1 | $2,991 | a/o May 23, 2013 |
| Shares Outstanding | 29,911,602 | a/o Feb 10, 2012 |
| Float | Not Available | |
| Authorized Shares | 200,000,000 | a/o Jun 09, 2011 |
| Par Value | 0.001 |
Shareholders
| Shareholders of Record | 801 | a/o May 25, 2011 |
Short Selling Data
| Short Interest | 18 (38.46%) May 15, 2013 |
| Significant Failures to Deliver | No |
Transfer Agent(s)
| Corporate Stock Transfer, Inc. |
1Market Value calculated only for respective security



